Prostaglandin E2 (PGE2) in portal blood in patients with pancreatic tumora single institution series

Journal of Investigative Surgery

Volumn 25, Issue 1, 2012, Pages 8-13

  Hogendorf, Piotr ^a   DurczyÅski, Adam ^a   Kumor, Anna ^a   Strzelczyk, Janusz ^a  

^a N Barlicki University Hospital No 1 of Medical University of Lodz   (Poland)

Author keywords

Chronic pancreatitis; COX 2; Cyclooxygenase 2; Pancreatic cancer; PGE2; Portal blood; Prostaglandin E2; Prostaglandins

Indexed keywords

PROSTAGLANDIN E2;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CHRONIC PANCREATITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; INTRAOPERATIVE PERIOD; MALE; PANCREAS ADENOCARCINOMA; PANCREAS DUCT; PANCREAS DUCT ADENOCARCINOMA; PORTAL VEIN; PORTAL VEIN BLOOD; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; CARCINOMA, PANCREATIC DUCTAL; DIAGNOSIS, DIFFERENTIAL; DINOPROSTONE; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; PORTAL VEIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84856324710     PISSN: 08941939     EISSN: 15210553     Source Type: Journal    
DOI: 10.3109/08941939.2011.592569     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2008;58:71-96.
2. Ries LAG, Harkins D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2003. Bethesda, MD: National Cancer In-situte.
3. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. International pancreatitis study group. N Engl J Med. 1993;328:1433-1437. (Pubitemid 23143844)
4. Talamini G, Bassi C, Falconi M, et al. Early detection of pancreatic cancer following the diagnosis of chronic pancreatitis. Digestion 1999;60:554-561. (Pubitemid 29495665)
5. Howes N, Neoptolemos JP. Risk of pancreatic ductal ade-nocarcinoma in chronic pancreatitis. Gut 2002;51:765-766. (Pubitemid 35408590)
6. Maisonneuve P, Lowenfels AB. Chronic pancreatitis and pancreatic cancer. Dig Dis. 2002;20:32-37.
7. Williams CS, Mann M, DuBois RN. The role of cyclooxyge-nases in infammation, cancer, and development. Oncogene 1999;18:7908-7916. (Pubitemid 30066236)
8. Kokawa A, Kondo H, Gotoda T, et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 2001;91:333-338. (Pubitemid 32099234)
9. Merati K, Siadaty M, Andea A, et al. Expression of infam-matory modulator COX-2 in pancreatic ductal adenocarci-noma and its relationship topathologic and clinical parameters. Am J Clin Oncol. 2001;24:447-452. (Pubitemid 32959100)
10. Okami J, Yamamoto H, Fujiwara Y, et al. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res. 1999;5:2018-2024. (Pubitemid 29399253)
11. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 1999;59:987-990. (Pubitemid 29135954)
12. Wang HX, Chen QK. Expression and signifcance of cyclooxygenase-2 in human pancreatic carcinomas. Ai Zheng. 2003;22:649-652. (Abst.)
13. Kong G, Kim EK, Kim WS, et al. Role of cyclooxygenase-2 and inducible nitric oxide synthase in pancreatic cancer. J Gastroenterol Hepatol. 2002;17:914-921.
14. Yip-Schneider MT, Barnard DS, Billings SD. Cyclooxygenase-2 expression in human pancreatic adeno-carcinomas. Carcinogenesis 2000;21:139-146. (Pubitemid 30098694)
15. Schlosser W, Schlosser S, Ramadani M, et al. Cyclooxygenase-2 is overexpressed in chronic pancreatitis. Pancreas 2002;25:26-30. (Pubitemid 34760832)
16. Maitra A, Ashfaq R, Gunn CR, et al. Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging. Am J Clin Pathol. 2002;118:194-120.
17. Nijima M, Yamaguchi T, Ishihara T, et al. Im-munohistochemical analysis and in situ hybridization of cyclooxygenase-2 expression in intraductalpapillary-mucinous tumors of the pancreas. Cancer 2002;94:1565-1573. (Pubitemid 34212652)
18. Koshiba T, Hosotani R, Miyamoto Y. Immunohistochem-ical analysis of cyclooxygenase-2 expression in pancreatic tumors. Int J Pancreatol. 1999;26:69-76.
19. Matsubayashi H, Infante JR, Winter J, et al. Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer. Cancer Biol Ther. 2007;6:1569-1575. (Pubitemid 351590328)
20. Ferreira SH, Vane JR. Prostaglandins: their dissappear-ance from and release into the circulation. Nature (Lond.) 1967;216:868-873.
21. Piper PJ, Vane JR; Wyllie JH. Inactivation of prostaglandins by the lungs. Nature (Lond.) 1970;225:600-604.
22. Ding XZ, Tong WG, Adrian TE. Cyclooxygenases and lipoxygenases as potential targets for treatment of pancreatic cancer. Pancreatology 2001;1:291-299. (Pubitemid 33758405)
23. Williams JA, Shacter E. Regulation of macrophage cy-tokine production by prostaglandin E2: distinct roles of cyclooxygenase-1 and-2. J Biol Chem. 1997;272:25693-25699. (Pubitemid 27438886)
24. Hotz HG, Hines OJ, Masood R. VEGF antisense therapy inhibits growth and improves survival in experimental pancreatic cancer. Surgery 2005;137:192-199. (Pubitemid 40174428)
25. Oka M, Inaba A, Uchiyama T, et al. Prostaglandin E2 levels and lymphocyte subsets In portal venous drainage of col-orectal cancer. Am J Surg. 1994;167:264-267.
26. Darwish AA, Sokal E, Stephenne X, et al. Pernament access to the portal system for cellular transplantation us-ing an implantable port device. Liver Transpl. 2004;10:1213-1215. (Pubitemid 39248423)
27. Graham ML, Mutch LA, Rieke EF, et al. Long-term hepatic vascular access in the nonhuman primate for recurrent portal vein infusion. J Invest Surg. 2011;24:59-66.
28. Yamaguchi K. How to defne patients at high risk for pancreatic cancer. Pancreatology 2011;11(Suppl. 2):3-6.
29. Kamisawa T, Takuma K, Tabata T, et al. Long-term follow-up of chronic pancreatitis patients with K-ras mutation in the pancreatic juice. Hepatogastroenterology 2011;58:174-176.
30. Milella M, Gelibter A, Di Cosimo S, et al. Pilot study of celecoxib and infusional 5-fuorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 2004;101:133-138. (Pubitemid 38812432)